Blog dedicated to the continuous education in Gynecology and Endocrinology

 

EFFECTS OF MENOPAUSE AND TIBOLONE ON DIFFERENT CARDIOVASCULAR BIOMARKERS IN HEALTHY WOMEN

DGYE-2010-0009.R1[488770]

Vassalle, Cristina; Mercuri, Antonella; Maffei, Silvia; Lello, Stefano

Background and Aim: The effects of tibolone on cardiovascular risk is not yet fully understood today. We designed this study to assess the effect of the menopausal status and tibolone treatment (2.5 mg/day for 3 months) on different biomarkers of cardiovascular risk. more

Post to Twitter Post to Facebook

Metabolic and hormonal parameters in postmenopausal women ten years after transdermal estradiol treatment, alone or combined to micronized oral progesterone

DGYE-2010-0019.R1

Pérez-López, Faustino; Cuadros-López, José; Fernández-Alonso, Ana; Chedraui, Peter; Sabatel-López, Rosa; Cuadros-Celorrio, Angela

Background. In a post-WHI era few postmenopausal women complete long term hormonal treatment (HT). Objective. To analyze metabolic/hormonal parameters and frequency of the metabolic syndrome (METS) in postmenopausal women after 10 years of HT. Methods. Retrospective data from parallel cohorts of postmenopausal women receiving HT for 10 years was analyzed. more

Post to Twitter Post to Facebook

Effects of Early-Initiated Estrogen Replacement Therapy on Plasma Homocysteine Levels in Women in Surgically-Induced Menopause

DGYE-2010-0005.R1[487610 ]

YUKSEL, Hasan (contact); ÇOBANOĞLU, MİNEGÜL; ODABAŞI, ALİ RIZA; SEZER, SELDA DEMİRCAN; Küçük, Mert; SERTER, MUKADDER

Objective: The aim of this study was to investigate and to compare the effects on serum homocysteine levels of early-initiated oral and transdermal estrogen replacement therapies given to women without a uterus who had undergone surgically-induced menopause. Homocysteine levels are considered one of the predictors of cardiovascular disease risk. Methods: This study included 45 women with surgical menopause. more

Post to Twitter Post to Facebook

HORMONAL THERAPY WITH ESTRADIOL AND TESTOSTERONE IMPLANTS: BONE PROTECTION?

DGYE-2009-0265.R1[489131]
Britto, Renata; Araújo, Leila; Barbosa, Ione; Silva, Lidia; Rocha, Sidnéia; Valente, Ana

Objective: To assess bone mineral density (BMD) in post menopausal women using estradiol and testosterone hormonal implants comparing to that of patients without hormonal therapy. Design of the study: 61 patients were followed in prospective cohort study separated in Group 1, 34 women using implants and group 2, 27 women without implants and BMD assessment through Dual Energy X-ray Absorptiometry was conducted in the beginning of follow-up and after 1 year. more

Post to Twitter Post to Facebook

Safety and Tolerability of Testosterone Patch Therapy for up to 4 Years in Surgically Menopausal Women Receiving Oral or Transdermal Estrogen

DGYE-2009-0263.R1[487597 ] Khadilkar, Anuradha; Kadam, Nidhi; Chiplonkar, Shashi; Divate, Uma; Khadilkar, Vaman

Two clinical trials previously demonstrated the safety of 300 mcg/day transdermal testosterone patch (TTP) treatment for up to 6 months in 1094 surgically menopausal women with hypoactive sexual desire disorder (HSDD). Adverse events (AE), clinical laboratory tests, vital signs, physical examinations, and mammograms were evaluated in open-label extensions of these two trials for up to 4 years and are presented in this paper. more

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy